PrintTRIALS AND TRIBULATIONS:
Pfizer Halts Trial of Pain DrugThe weekly round-up of failed trials, missed targets and other business mishaps.
Pfizer said it was halting a trial of its experimental drug tanezumab to treat chronic low back pain and diabetic peripheral neuropathy at the request of the U.S. Food and Drug Administration. Investigation of the compound continues in some areas of high unmet medical need, including cancer pain, the pharmaceutical company said.
Read More
Drug Development
Recommendation Reversal FDA panel says Avastin shouldn’t be marketed for breast cancer. Read More.Drug Development
Mannkind Tries AgainBiopharma resubmits application for inhaled insulin to FDA. Read More.Business Development
FDA Panel Rejects Vivus Fat PillReviewers vote 10-6 against recommending approval of obesity drug because of safety concerns. Read More.Trials and Tribulations
GSK To Take $2.36 Billion Charge for Legal SettlementsThe weekly round-up of failed trials, missed targets and other business mishaps. Read More.Business Strategy
Genyme Expands Manufacturing Plans Amid TroublesMeanwhile, investors and company are placing bets on its prospects. Read More.Drug Development
Merck Wins Approval for MS drug in RussiaFirst oral drug for multiple sclerosis expected to launch in early 2011. Read More.Business Strategy
Takeda Looking for ProductsJapanese pharma adds $569 million to acquisition kitty Read More.Drug Development
Genentech Seeks FDA Approval for New Breast Cancer DrugDrug aimed at patients with recurrent cancer when Herceptin and other drugs have already been used. Read More.Trials and Tribulations
U.S. and European Regulators Examine Safety of GSK’s AvandiaThe weekly round-up of failed trials, missed targets and other business mishaps. Read More.Drug Development
Chasing a Fat OpportunityBig dollars and promising results heat up the race to bring new obesity therapies to market. Read More.Trials and Tribulations
Two Studies Add to Concerns Over GSK's AvandiaThe weekly round-up of failed trials, missed targets and other business mishaps. Read More.On the Move
Taking a Giant LeapExelixis CEO George Scangos named new CEO of Biogen Idec. Read More.Business Strategy
Beefing UpAmyris seems to want to reassure wary investors by adding muscle prior to going public. Read More.Trials and Tribulations
Despite Positive Results, Affymax Tanks as Investors Worry About Safety of Anemia Drug The weekly round-up of failed trials, missed targets and other business mishaps. Read More.Business Development
Not TonightBoehringer Ingelheim’s female libido booster fails to excite FDA reviewers. Read More.
.gif)
.gif)
- Pfizer's Viagra Weighed by U.S. FDA for Children With Rare Lung Disorder
Bloomberg - New Health Official Faces Hostility in Senate
The New York Times - Pharma seeks FDA clarity on risky drug safeguards
Reuters - Special report: Targeting teens for gastric bands
Reuters - Genzyme Said to Rebuff Sanofi-Aventis Takeover Approach; Genzyme Advances
Bloomberg - Sanofi makes approach to Genzyme -sources
Reuters - Sanofi-Aventis’s Biotech Play for Genzyme
The New York Times - U.S. advisers reject Vivus fat-fighting pill
Reuters - PhRMA Names Business Roundtable's Castellani as CEO, Beginning Sept. 1
Bloomberg - Vivus' fat pill works; safety a concern-FDA staff
Reuters